However, COVID-19 patients who had been treated with Type I IFN had approximately the same or slightly higher odds of developing acute pericarditis (OR [95% CI]: 1.00 [0.41, 2.45]), heart failure (OR [95% CI]: 1.58 [0.69, 3.58]), acute myocardial infarction (OR [95% CI]: 1.03 [0.42, 2.53]), and pulmonary embolism (OR [95% CI]: 1.06 [0.44, 2.60]). Here, IFNA1 is linked to COVID-19.